tradingkey.logo

BRIEF-Sanofi's Extraintestinal Pathogenic E. Coli Vaccine Fails To Show Sufficient Efficacy In Phase 3 Clinical Study

ReutersFeb 13, 2025 6:09 AM

- Sanofi SA SASY.PA:

  • PRESS RELEASE: UPDATE ON EXTRAINTESTINAL PATHOGENIC E. COLI VACCINE PHASE 3 CLINICAL STUDY

  • VACCINE CANDIDATE FAILS TO SHOW SUFFICIENT EFFICACY

  • NO SAFETY SIGNALS IDENTIFIED FOR E. COLI VACCINE CANDIDATE

  • E.MBRACE PHASE 3 STUDY DISCONTINUED

  • RECORDS $250 MILLION IMPAIRMENT CHARGE IN Q4 2024

  • FULL-YEAR IFRS EPS ADJUSTED TO €4.44 FROM €4.59

  • MAINTAINS 2025 FINANCIAL GUIDANCE

Source text: ID:nGNX6mXTG

Further company coverage: SASY.PA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI